Details of the Drug Combination

General Information of Drug Combination (ID: DCGE3UU)

• Drug Combination Name: FORMESTANE + Pentostatin
• Indication: Glioma; Status: Investigative [1]
• Component Drugs:
  FORMESTANE (DMWIDJK): Small molecular drug
  Pentostatin (DM0HXDS): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: SF-539
  Zero Interaction Potency (ZIP) Score: 5.47
  Bliss Independence Score: 10.4
  Loewe Additivity Score: 3.85
  LHighest Single Agent (HSA) Score: 2.65

Molecular Interaction Atlas of This Drug Combination

Indication(s) of FORMESTANE

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Withdrawn from market	[2]

FORMESTANE Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[5]

FORMESTANE Interacts with 5 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Adenylate kinase isoenzyme 1 (AK1)	OT614AR3	KAD1_HUMAN	Increases ADR	[6]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Decreases Activity	[7]
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)	OT6EBDHM	DHB1_HUMAN	Decreases Activity	[8]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Increases Expression	[9]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Increases Expression	[9]

Indication(s) of Pentostatin

Disease Entry	ICD 11	Status	REF
Acute graft versus host disease	4B24.0	Approved	[3]
Hairy cell leukaemia	2A82.2	Approved	[4]
Leukemia	N.A.	Approved	[3]

Pentostatin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Adenosine deaminase (ADA)	TTLP57V	ADA_HUMAN	Inhibitor	[10]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DCC7ATE	HCC-2998	Investigative	[1]
Adult acute myeloid leukemia	DC8V3K9	HL-60(TB)	Investigative	[1]
Anaplastic large cell lymphoma	DCDSRGS	SR	Investigative	[1]
Astrocytoma	DCXA4BN	U251	Investigative	[1]
Lung adenocarcinoma	DCRCCVT	EKVX	Investigative	[1]
Non-small cell lung carcinoma	DCC22L8	HOP-92	Investigative	[1]
Pleural epithelioid mesothelioma	DCO0WTC	NCI-H226	Investigative	[1]
Renal cell carcinoma	DCZTJDI	UO-31	Investigative	[1]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Pentostatin FDA Label
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4805).
• [5] The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
• [6] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [7] Screening of selected pesticides for inhibition of CYP19 aromatase activity in vitro. Toxicol In Vitro. 2000 Jun;14(3):227-34.
• [8] Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol. 2005 Apr;94(5):461-7.
• [9] Androgen- and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites in yeast based assays. Toxicol Lett. 2018 Aug;292:39-45. doi: 10.1016/j.toxlet.2018.04.026. Epub 2018 Apr 24.
• [10] Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5.